Eagle Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Woodcliff Lake NJ United States (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2008
NCT01045018
First Marketed Drug
2011
argatroban
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Eagle Pharmaceuticals, Inc. | EAGLE PHARMS

Active Ingredients

Marketed Drugs (6)

argatroban (2011)

bendamustine (treanda) (2015)

dantrolene (dantrium) (2014)

docetaxel (taxotere) (2015)

pemetrexed (alimta) (2020)

vasopressin (vasostrict) (2021)

Drugs in Phase 3 Trials (2)

dantrolene (dantrium) (3 trials)

mesalamine (rowasa) (1 trial)

Drugs in Phase 2 Trials (1)

cal02 (1 trial)

Drugs in Phase 1 Trials (2)

bendamustine (treanda) (1 trial)

fulvestrant (faslodex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Heat Stroke (Phase 3)

Stroke (Phase 2)

Sunstroke (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5